プロフィール

登録日: 3ヶ月、 1週前

Ry thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin

 

Ry thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab. 2005;90(9):5270?. doi:10.1210/jc.2005-0271. 46. Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, et al. In papillary thyroid carcinoma brafv600e is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol (Oxf). 2012;77(5):780?. doi:10.1111/j.1365-2265.2012.04465.x. 47. Ulisse S, Baldini E, Sorrenti Dovitinib S, Barollo S, Gnessi L, Catania A, et al. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96(2):504?. doi:10.1210/jc.2010-1688. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28545970 48. Sid B, Dedieu S, Delorme N, Sartelet H, Rath GM, Bellon G, et al. Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator. Int J Biochem Cell Biol. 2006;38(10):1729?0. doi:10.1016/j.biocel.2006.04.005.Espinal-Enr uez et al. BMC Genomics (2015) 16:Page 22 of49. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol. 2008;15(10): 2811?6. doi:10.1245/s10434-008-0034-8. 50. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, et al. Upregulation of hmga2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer. 2008;47(1):56?3. doi:10.1002/gcc.20505. 51. Chiappetta G, Botti PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/29031867 G, Monaco M, Pasquinelli R, Pentimalli F, Bonito MD, et al. Hmga1 protein overexpression in human breast carcinomas: correlation with erbb2 expression. Clin Cancer Res. 2004;10(22):7637?4. doi:10.1158/1078-0432.CCR-04-0291. 52. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, et al. A phase ii study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975?0. doi:10.1089/thy.2010.0057. 53. Zhang J, Wang P, Dykstra M, Gelebart P, Williams D, Ingham R, et al. Platelet-derived growth factor receptor- promotes lymphatic metastases in papillary thyroid cancer. J Pathol. 2012;228(2):241?0. doi:10.1002/path.4069. 54. Che H-Y, Guo H-Y, Si X-W, You Q-Y, Lou W-Y. Additive effect by combination of akt inhibitor, mk-2206, and pdgfr inhibitor, tyrphostin ag 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. Onco Targets Ther. 2014;7:425?2. doi:10.2147/OTT.S57324. 55. Chen K-T, Lin J-D, Liou M-J, Weng H-F, Chang CA, Chan E-C. An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett. 2006;231(2):192?05. doi:10.1016/j.canlet.2005.01.039. 56. Lum AM, Wang BB, Beck-Engeser GB, Li L, Channa N, Wabl M. Orphan receptor gpr110, an oncogene overexpressed in lung and prostate cancer. BMC Cancer. 2010;10:40. doi:10.1186/1471-2407-10-40. 57. Zhang D, Ren W-H, Gao Y, Wang N-Y, Wu W-J. Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer. Asian Pac J Cancer Prev. 2013;14(7):4215?1. 58. Tosi F, Sarra DD, Bonin C, Zambotti F, Dall'Alda M, Fiers T, et al. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary synd.

サイト: https://www.medchemexpress.com/Siramesine-hydrochloride.html

---

フォーラム

開始したトピック: 0

返信: 0

フォーラム権限グループ: 閲覧者